On November 13, 2026, a new publication titled "Real-world experience with oral on-demand treatment sebetralstat for hereditary angioedema in a retrospective case series" appeared in Allergy and Asthma Proceedings. The publication is indexed under PubMed ID 43025858. It is described as a retrospective case series examining real-world use of oral on-demand sebetralstat in patients with hereditary angioedema. No findings, outcomes, or efficacy data from the publication have been provided alongside this listing. This item is noted in relation to hereditary angioedema treatment research, an area that also includes icatibant, which remains an approved therapy for this condition. The publication record does not include specific results, safety conclusions, or comparative data between sebetralstat and other hereditary angioedema treatments. Readers interested in the broader context of hereditary angioedema management options can review the compound overview for icatibant to better understand its approved status and treatment background. This brief reflects only the bibliographic details supplied: the title, journal, publication date, and identifier. No additional claims about treatment benefit or harm can be drawn from this information alone. Further details would require direct review of the full publication text.
Publication Covers Sebetralstat Case Series, Related to Icatibant's HAE Field
See the full icatibant overview
Source: https://pubmed.ncbi.nlm.nih.gov/43025858/